ERBB2 and breast cancer: An in vitro study by Weingaertner et al. demonstrated a significant reduction in Heregulin-induced cellular growth and increase in cellular apoptosis determined by a chronic treatment with morphine in a human epidermal growth factor receptor 2 (HER2)-positive human breast cancer cell line [54].